Top Penny Stocks To Watch In August 2026

The market remained flat over the last week, but it is up 20% over the past year, with earnings forecast to grow by 17% annually. Though the term 'penny stock' might sound like a relic of past trading days, these smaller or newer companies can still offer significant opportunities when built on solid financials. We've selected three examples of penny stocks that combine balance sheet strength with potential for outsized gains, giving investors the chance to discover hidden value in quality companies.

Let's uncover some gems from our specialized screener.

Oramed Pharmaceuticals (ORMP)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Oramed Pharmaceuticals Inc. focuses on the research and development of pharmaceutical solutions utilizing a technology platform for the oral delivery of therapeutic proteins, with a market cap of approximately $190.10 million.

Operations: Oramed Pharmaceuticals Inc. does not report any revenue segments.

Market Cap: $190.1M

Oramed Pharmaceuticals Inc. has recently transitioned to profitability, achieving substantial net income growth with US$78.16 million reported for Q2 2026, up from US$13.29 million the previous year. The company's strong financial position is underscored by its debt-free status and a robust return on equity of 55.1%. Despite being pre-revenue with less than US$1 million in sales, Oramed's inclusion in multiple Russell indexes highlights its growing market recognition. Its seasoned management and board further bolster investor confidence in navigating the volatile penny stock landscape effectively while maintaining a low price-to-earnings ratio of 1.1x compared to the broader market.

• Dive into the specifics of Oramed Pharmaceuticals here with our thorough balance sheet health report.
• Explore historical data to track Oramed Pharmaceuticals' performance over time in our past results report.

AGNT (AGNT)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: AGNT, Inc, along with its subsidiaries, offers cloud-based real estate brokerage services for residential homeowners and homebuyers, with a market cap of $733.65 million.

Operations: The company's revenue is primarily derived from North American Realty at $4.79 billion and International Realty at $169.48 million, supplemented by Other Affiliated Services totaling $2.88 million.

Market Cap: $733.65M

AGNT, Inc. is navigating the penny stock landscape with a focus on cloud-based real estate brokerage services, reporting US$4.79 billion in North American Realty revenue. The company remains unprofitable but offers a dividend yield of 4.56%, although not covered by earnings. AGNT's management and board are experienced, averaging 2.3 and 6 years respectively, while its debt-free status and no long-term liabilities enhance financial stability despite increased losses over five years at a rate of 73.6% annually. Recent guidance anticipates up to US$5.15 billion in annual revenue amid macroeconomic challenges, with stable weekly volatility at 9%.

• Get an in-depth perspective on AGNT's performance by reading our balance sheet health report here.
• Evaluate AGNT's prospects by accessing our earnings growth report.

Cerus (CERS)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Cerus Corporation is a biomedical products company with a market cap of $598.53 million.

Operations: The company generates revenue primarily from its Blood Safety segment, which accounted for $221.55 million.

Market Cap: $598.53M

Cerus Corporation, operating within the penny stock realm, has shown resilience by reducing its net loss significantly over the past year. Despite being unprofitable, it has improved earnings and forecasts suggest continued growth. The company's financial structure is solid with short-term assets exceeding both short- and long-term liabilities, and a satisfactory net debt to equity ratio of 12.2%. Recent strategic moves include raising its earnings guidance for 2026 and securing a $110 million debt facility to support business expansion. However, investor concerns about governance and profitability persist amidst stable weekly volatility at 11%.

• Unlock comprehensive insights into our analysis of Cerus stock in this financial health report.
• Assess Cerus' future earnings estimates with our detailed growth reports.

Summing It All Up

• Unlock more gems! Our US Penny Stocks screener has unearthed 320 more companies for you to explore.Click here to unveil our expertly curated list of 323 US Penny Stocks.
• Want To Explore Some Alternatives? Trump has pledged to "unleash" American oil and gas and these 23 US stocks have developments that are poised to benefit.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com